Curis Announces Orphan Drug Designation for CUDC-907 in Diffuse Large B-Cell Lymphoma

Industry News

The FDA has granted Orphan Drug Designation for CUDC-907 for the treatment of diffuse large B-cell lymphoma (DLBCL).  CUDC-907 is being developed by the Lexington, MA based biotechnology company Curis.  It is an oral and dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K).  DLBCL is an aggressive and a common subtype of Non-Hodgkin lymphoma, a heterogeneous group of cancer involving lymphocytes.  DLBCL is curable in the majority of patients; however, one of the greatest unmet medical needs is prevention and treatment of relapsed or refractory disease.  CUDC-907 is currently under clinical trials in patients with relapsed or refractory lymphomas or multiple myeloma as well as in patients with advanced/ relapsed solid tumors.


Original Article:

Subscribe to WXPress

Receive our newsletter and information on upcoming events.